These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1005910)

  • 1. Chemical structure and aldosterone receptor affinity of canrenoate-potassium metabolites in rabbits.
    Finn AM; Finn C; Sadée W
    Res Commun Chem Pathol Pharmacol; 1976 Dec; 15(4):613-25. PubMed ID: 1005910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution of 3H-canrenoate potassium in rabbits.
    Finn AM; Brown R; Sadée W
    J Pharm Sci; 1977 Feb; 66(2):275-7. PubMed ID: 839430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolism of canrenone in vitro by rat liver preparations.
    Boreham DR; Vose CW; Palmer RF; Slater TF; Cheeseman K
    Xenobiotica; 1981 Apr; 11(4):231-40. PubMed ID: 7303717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Letter: Labelled spironolactones. Possible tracers in renal scintigraphy].
    Paulin R
    Nouv Presse Med; 1974 Dec; 3(44):2662. PubMed ID: 4459860
    [No Abstract]   [Full Text] [Related]  

  • 7. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 8. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope-labeling techniques.
    Vose CW; Boreham DR; Ford GC; Haskins NJ; Palmer RF
    Drug Metab Dispos; 1979; 7(4):226-32. PubMed ID: 39725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioestrogenic action of the aldosterone antagonist canrenoate K in the rat (adenohypophysis, ceruloplasmin).
    Schreiber V; Pribyl T
    Physiol Bohemoslov; 1977; 26(5):385-95. PubMed ID: 144921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal clearance of canrenoate in normal man.
    Hofmann LM; Polk RC; Maibach HI
    Clin Pharmacol Ther; 1975 Dec; 18(6):748-56. PubMed ID: 1204280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships of the molecular structure of aldosterone derivatives with their binding affinity for mineralocorticoid receptor.
    Yamakawa M; Ezumi K; Shiro M; Nakai H; Kamata S; Matsui T; Haga N
    Mol Pharmacol; 1986 Dec; 30(6):585-9. PubMed ID: 3023811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites.
    Los LE; Pitzenberger SM; Ramjit HG; Coddington AB; Colby HD
    Drug Metab Dispos; 1994; 22(6):903-8. PubMed ID: 7895608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone plasma radioimmunoassay interference by a spirolactone metabolite.
    Sadée W; Finn AM; Schmiedek P; Baethmann A
    Steroids; 1975 Mar; 25(3):301-11. PubMed ID: 1145668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat.
    Bos R; Mougenot N; Médiani O; Vanhoutte PM; Lechat P
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1160-6. PubMed ID: 14764658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.